Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia

NCT03672851 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped adverse effect

Conditions

Acute Leukemia
Acute Leukemia in Relapse
Acute Myeloid Leukemia
Relapsed or Refractory Acute Leukemia

Interventions

DRUG: anti-CD123 CAR-T treatment

Sponsor

Second Affiliated Hospital of Xi'an Jiaotong University

Collaborators

[object Object]